955028-82-7

Usage

Uses

Used in Pharmaceutical Synthesis:
Trans-tert-butyl 4-fluoro-3-hydroxypiperidine-1-carboxylate is used as a building block in the synthesis of various pharmaceuticals and organic compounds. Its unique structural features make it a valuable component in the development of new drugs and medicinal agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, trans-tert-butyl 4-fluoro-3-hydroxypiperidine-1-carboxylate is utilized for its potential applications in drug discovery. Its structural properties allow for the creation of novel compounds with potential therapeutic effects.
Used in Organic Synthesis:
Trans-tert-butyl 4-fluoro-3-hydroxypiperidine-1-carboxylate is employed as a key intermediate in organic synthesis, where its stability and reactivity contribute to the formation of complex organic molecules for various applications.

InChI:InChI=1/C10H18FNO3/c1-10(2,3)15-9(14)12-5-4-7(11)8(13)6-12/h7-8,13H,4-6H2,1-3H3

Upstream product

• 161157-50-2 tert-butyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 
• 131667-57-7 tert-butyl 1,2,3,4-tetrahydro-1-pyridinecarboxylate 
• 1174020-46-2 racemic trans-tert-butyl 4-fluoro-3-hydroxypiperidine-1-carboxylate 

Downstream Products

• 1638765-12-4 racemic trans-4-fluoropiperidin-3-ol hydrochloride 
• 1174020-46-2 racemic cis-tert-butyl 4-fluoro-3-hydroxypiperidine-1-carboxylate 
• 1638765-12-4 racemic cis-4-fluoropiperidin-3-ol hydrochloride 
• 1638765-12-4 (3SR,4SR)-4-fluoro-piperidin-3-ol hydrochloride 

Relevant academic research and scientific papers

1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS

1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS

The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

PYRROLOPYRIDINES AS KINASE INHIBITORS

Compounds of Formula (I) are useful for inhibition of CHKl and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.